Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Arbor Biotechnologies™, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the...
-
CAMBRIDGE, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the...
-
– Presentations demonstrate progress in advancing portfolio of CNS gene editing programs in SOD1 ALS and first data presented on company’s Angelman syndrome program – Data showcase specificity...
-
– Data from oral presentation supported ABO-101 IND and CTA approval for clinical assessment in primary hyperoxaluria type 1 (PH1) in the Phase 1/2 redePHine study in US and UK (NCT06839235) – ...
-
- Oral presentation to include preclinical data supporting the clinical advancement of ABO-101 for the treatment of primary hyperoxaluria type 1 - Four poster presentations collectively demonstrate...
-
Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into 2027 and supports the clinical development of...
-
Orphan Drug and Rare Pediatric Disease designations follow U.S. FDA acceptance of IND application for ABO-101 for the treatment of PH1, with Phase 1/2 trial initiation anticipated in H1 2025. IPNA...
-
CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Arbor Biotechnologies™, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that the U.S....
-
Oral presentation at ASN on lead program, ABO-101 for primary hyperoxaluria type 1 (PH1), supporting in vivo proof of pharmacology. On-track for year-end IND/CTA filing.Oral presentation at ALS One...
-
Presented data which, along with ongoing IND-enabling studies, demonstrate efficacy and pharmacology of ABO-101 in non-human primates (NHPs), supporting continued development as a potential novel gene...